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Cancer is a disease of the genome and the epigenome. Previous studies have shown that genomic changes
such as mutations, copy number variation, and genomic rearrangements drive cancer evolution. In this
issue of Cancer Cell, Landau and colleagues add epigenomic changes, specifically locally disordered DNA
methylation, to cancer’s evolutionary trajectory.Deep genomic sequencing technologies
are beginning to resolve the underlying
complexities of solid and hematologic
cancers. Peter Nowell’s proposed model
for cancer evolution suggesting that
cancers evolve through branched evolu-
tionary trajectories fuelled by genomic
instability is now increasingly being
accepted as a basis for therapeutic failure
and the increasing mismatch between
cost and clinical benefit from current
targeted therapeutic approaches (Nowell,
1976). As Nowell predicted in 1976, ‘‘One
may ultimately have to consider each
advanced malignancy as an individual
therapeutic problem.’’
Work over the last three decades has
revealed how diversity within tumors can
be driven at many levels. Genomic insta-
bilities can be initiated by deficiencies
in DNA repair, DNA replication stress,
telomere dysfunction, genome doubling
events, and mitotic aberrations resulting
in abnormal chromosome-spindle attach-
ments precipitating whole chromosomal
instabilities (reviewed in Burrell et al.,
2013). Such genome instability processes
may also be dynamic over space and
time. As the resolution of cancer genomic
analysis improves, so does an apprecia-
tion that the majority of solid tumors har-
bor at least one mechanism of genome
instability that promotes further evolution
and adaptation.
It has been appreciated for many years
that diversity within individual tumors,
manifested by chromosomal instability,
is associated with poor outcome. Deep
sequencing analyses have added to
these observations. For example, through
deep sequencing analysis of chronic lym-
phocytic leukemia (CLL), the presence of
subclonal driver events was associatedwith poorer outcome (Landau et al.,
2013). Emerging data suggest that diver-
sity at any level is sufficient to influence
clinical outcomes. Indeed, Carlo Maley
and colleagues investigated this pro-
position in Barrett’s esophagus, the
preinvasive stage preceding the onset of
esophageal carcinoma, examining multi-
ple genetic and epigenetic drivers of
diversity. The authors concluded that
all diversity measures, both genetic and
epigenetic, were strongly associated
with clinical risk of progression (Merlo
et al., 2010).
It is also appreciated that genetically
similar cells may behave differently in the
face of identical selection pressures.
Altered epigenetic states are thought to
be a mechanism through which these
observations can be explained. For ex-
ample, minority drug tolerant persistor
cells result in drug resistance dependent
on the histone demethylase JARID1A,
which can be both dynamic and transient
(Sharma et al., 2010). These data suggest
the need for a comprehensive under-
standing of both the cancer genome
and epigenome to predict tumor cell
behavior. It is the understanding of the
latter into which the study in this issue of
Cancer Cell by Landau et al. (2014) sheds
new light.
A defining feature of epigenetics is the
ability to stably switch between different
biological states. Typically, this can result
in the expression of affected genes to be
switched on or off or genome stability to
be maintained or impaired. This process
of switching allows for many different ge-
netic programs to be run from the same
genome, giving rise to many different epi-
genomes. The temporal and spatial regu-
lation of these epigenomes are exquisitelyCancer Cell 26,controlled during normal development
but severely disrupted in cancer. A com-
mon mechanism for epigenomic disrup-
tion is stochasticity, whereby changes
are introduced randomly that lead to
gain or loss of DNA methylation at certain
CpG dinucleotides, the preferred sites of
DNA methylation in mammalian cells
including cancer cells. In addition, such
seemingly stochastic changes may also
be mediated by genetic variants as pro-
posed in the inherited stochastic variation
model, which provides a mechanism
to explain an epigenetic role in select-
able phenotypic variation (Feinberg and
Irizarry, 2010).
Figure 1A illustrates three common
scenarios of DNA methylation (DNAm)
changes that have been observed in mul-
tiple cancers by comparison with normal
tissue. As the name implies, variably
methylated regions (VMRs) display oscil-
lating gain and loss of DNAm. Their
‘‘noisy’’ appearance inspired a model
whereby the epigenome can modulate
cellular plasticity by regulating the effects
of noise and thus explain the observed
increase in VMRs and gene expression
contributing to cancer heterogeneity
(Pujadas and Feinberg, 2012). Regions
of long-range epigenetic silencing and
activation are defined by gain and loss
of DNAm, respectively, and have been
shown to remodel large domains of the
cancer epigenome (reviewed in Stirzaker
et al., 2014).
What differentiates the study by Landau
et al. (2014), which focuses on CLL from
previous studies investigating intratumor
DNAm heterogeneity, is that they used
deep bisulfite sequencing. This allowed
them to assess DNAm heterogeneity at
single molecules or reads derived fromDecember 8, 2014 ª2014 Elsevier Inc. 775
Figure 1. Illustration of Intratumor DNA Methylation Heterogeneity
(A) Major types of DNA methylation (DNAm) heterogeneity include variably
methylated regions (VMR), long-range epigenetic silencing (LRES), and
long-range epigenetic activation (LREA).
(B) Schematic bisulfite sequencing reads showing concordant (CR) and
discordant (DR) DNAm and formula for calculation of the proportion of discor-
dant reads (PDR).
(C) PDR differs in patients with chronic lymphocytic leukemia (CLL) and is
associated with adverse clinical outcome.
Cancer Cell
Previewsindividual cancer cells rather
than aggregated values from
populations of cancer cells.
As illustrated in Figure 1B,
some reads were found to
be methylation concordant
while others were found
to be discordant, consistent
with increased stochastic
heterogeneity in the corre-
sponding leukemic cells. To
quantify this heterogeneity,
the authors devised a new
measure—proportion of dis-
cordant reads (PDR)–which
provides an index for intratu-
mor DNAm heterogeneity
that is akin to the intratumor
heterogeneity ratio index al-
ready in use for quantifying
intratumor genetic heteroge-
neity from the TRACERx
study (Jamal-Hanjani et al.,
2014). By measuring the
PDR index across promoters
in a cohort of patients with
CLL, Landau et al. (2014)
established that increasing
PDR levels are associated
with adverse clinical outcome
(Figure 1C).
Looking ahead, the hope is
that this new approach will
improve our ability to deter-
mine, and one day attenuate,
the background DNAm incancer. This would thereby allow for
more accurate identification of positively
selected methylation changes, the elu-
sive epigenetic drivers of cancer progres-
sion and evolution. If successful, we will
be one step closer to solving Nowell’s
individualized therapeutic problem by776 Cancer Cell 26, December 8, 2014 ª201limiting the epigenetic fuel for cancer
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